Borrowing external information to improve Bayesian confidence propagation neural network
- PMID: 32488331
- DOI: 10.1007/s00228-020-02909-w
Borrowing external information to improve Bayesian confidence propagation neural network
Abstract
Purpose: A Bayesian confidence propagation neural network (BCPNN) is a signal detection method used by the World Health Organization Uppsala Monitoring Centre to analyze spontaneous reporting system databases. We modify the BCPNN to increase its sensitivity for detecting potential adverse drug reactions (ADRs).
Method: In a BCPNN, the information component (IC) is defined as an index of disproportionality between the observed and expected number of reported drugs and events. Our proposed method adjusts the IC value by borrowing information about events that have occurred in drugs defined as similar to the target drug. We compare the performance of our method with that of a traditional BCPNN through a simulation study.
Results: The false positive rate of the proposed method was lower than that of the traditional BCPNN method and close to the nominal value, 0.025, around the true difference in ICs between the target drug and similar drugs equal to 0. The sensitivity of the proposed method was much higher than that of the traditional BCPNN method in case in which the difference in ICs between the target drug and similar drugs ranges from 0 to 2. When applied to a database managed by Japanese regulatory authority, the proposed method could detect known ADRs earlier than the traditional method.
Conclusions: The proposed method is a novel criterion for early detection of signals if similar drugs have the same tendencies. The proposed BCPNN tends to have higher sensitivity when the true difference is greater than 0.
Keywords: Dynamic borrowing; Information component; Pharmacovigilance; Signal detection.
Similar articles
-
Criteria revision and performance comparison of three methods of signal detection applied to the spontaneous reporting database of a pharmaceutical manufacturer.Drug Saf. 2007;30(8):715-26. doi: 10.2165/00002018-200730080-00008. Drug Saf. 2007. PMID: 17696584
-
Data mining in pharmacovigilance--detecting the unexpected: the role of index of suspicion of the reporter.Drug Saf. 2009;32(5):419-27. doi: 10.2165/00002018-200932050-00005. Drug Saf. 2009. PMID: 19419236
-
Data mining spontaneous adverse drug event reports for safety signals in Singapore - a comparison of three different disproportionality measures.Expert Opin Drug Saf. 2016 May;15(5):583-90. doi: 10.1517/14740338.2016.1167184. Epub 2016 Apr 7. Expert Opin Drug Saf. 2016. PMID: 26996192
-
Adverse event classification and signal detection of data from the customer service and pharmacovigilance of a multinational veterinary pharmaceutical company.Prev Vet Med. 2022 Sep;206:105704. doi: 10.1016/j.prevetmed.2022.105704. Epub 2022 Jul 1. Prev Vet Med. 2022. PMID: 35850073 Review.
-
Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.Health Technol Assess. 2011 May;15(20):1-234, iii-iv. doi: 10.3310/hta15200. Health Technol Assess. 2011. PMID: 21545758 Review.
Cited by
-
Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database.Front Pharmacol. 2022 Dec 15;13:1039867. doi: 10.3389/fphar.2022.1039867. eCollection 2022. Front Pharmacol. 2022. PMID: 36588707 Free PMC article.
-
Post-marketing safety of anakinra and canakinumab: a real-world pharmacovigilance study based on FDA adverse event reporting system.Front Pharmacol. 2025 Apr 30;16:1483669. doi: 10.3389/fphar.2025.1483669. eCollection 2025. Front Pharmacol. 2025. PMID: 40371323 Free PMC article.
-
Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancer.BMC Pulm Med. 2025 Feb 6;25(1):63. doi: 10.1186/s12890-025-03509-z. BMC Pulm Med. 2025. PMID: 39915804 Free PMC article.
-
Romosozumab adverse event profile: a pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS) from 2019 to 2023.Aging Clin Exp Res. 2025 Jan 14;37(1):23. doi: 10.1007/s40520-024-02921-5. Aging Clin Exp Res. 2025. PMID: 39808360 Free PMC article.
-
Immune checkpoint inhibitor-associated myocarditis and pericarditis: a pharmacovigilance study based on the FAERS database.BMC Cancer. 2025 Aug 9;25(1):1294. doi: 10.1186/s12885-025-14668-x. BMC Cancer. 2025. PMID: 40783691 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical